Cardoso Brito ACC, Oliveira Carneiro Ribeiro E, Freire de Melo F. Haploidentical hematopoietic stem cell transplantation as promising therapy in the improved survival of pediatric patients with leukemias and myelodysplasias. World J Meta-Anal 2023; 11(5): 181-195 [DOI: 10.13105/wjma.v11.i5.181]
Corresponding Author of This Article
Fabrício Freire de Melo, PhD, Professor, Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, 3293-3391-Candeias, Estrada do Bem Querer, Vitória da Conquista 45029-094, Bahia, Brazil. freiremeloufba@gmail.com
Research Domain of This Article
Oncology
Article-Type of This Article
Systematic Reviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Meta-Anal. Jun 18, 2023; 11(5): 181-195 Published online Jun 18, 2023. doi: 10.13105/wjma.v11.i5.181
Haploidentical hematopoietic stem cell transplantation as promising therapy in the improved survival of pediatric patients with leukemias and myelodysplasias
Ana Clara Carvalho Cardoso Brito, Everton Oliveira Carneiro Ribeiro, Fabrício Freire de Melo
Ana Clara Carvalho Cardoso Brito, Everton Oliveira Carneiro Ribeiro, Fabrício Freire de Melo, Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil
Author contributions: Cardoso Brito ACC, Oliveira Carneiro Ribeiro E, and Freire de Melo F equally contributed to this paper with the conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version; and all authors agree to be accountable for all aspects of the work in ensuring that questions that are related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Fabrício Freire de Melo, PhD, Professor, Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, 3293-3391-Candeias, Estrada do Bem Querer, Vitória da Conquista 45029-094, Bahia, Brazil. freiremeloufba@gmail.com
Received: February 10, 2023 Peer-review started: February 10, 2023 First decision: March 28, 2023 Revised: April 21, 2023 Accepted: May 16, 2023 Article in press: May 16, 2023 Published online: June 18, 2023
Core Tip
Core Tip: In recent years, the number of children under 18 years of age with leukemias and myelodysplasias undergoing haploidentical hematopoietic stem cell transplantation has increased. This type of transplant has been shown to be a promising therapy due to the availability of potential donors. The main objective is to identify the scientific contributions available on haploidentical hematopoietic stem cell transplantation performed with this audience. It has been observed that prognostic factors such as treatment platforms, cytogenetic abnormalities and disease status exert a strong influence on the clinical outcomes of transplant patients. Other variables can be obtained to collaborate with risk stratification and donor selection approaches.
